Recapping ASCO, talking cancer therapy combinations, and looking ahead – STAT

Posted: June 4, 2020 at 9:48 am

Before it even started, ASCO 2020 was one for the books. Held virtually for the first time in its history instead of at Chicagos massive McCormick Place conference center, the American Society of Clinical Oncologys big meeting also shrank from five days to three last weekend.

After following ASCO news from afar, STATs Adam Feuerstein on Wednesday continued in that vein, hosting a virtual chat with three noted oncologists to get their take on the future of cancer therapy. After big news from AstraZeneca in lung cancer, Johnson & Johnson in multiple myeloma, and Allogene in off-the-shelf gene therapy, they paused to reflect on their field and ASCO 2021. Here are some of their observations:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Go here to read the rest:
Recapping ASCO, talking cancer therapy combinations, and looking ahead - STAT

Related Posts